ATT.CN - Abattis Bioceuticals Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.18
-0.00 (-2.70%)
As of 10:56AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.19
Open0.19
Bid0.17 x 0
Ask0.18 x 0
Day's Range0.17 - 0.19
52 Week Range0.10 - 1.13
Volume506,151
Avg. Volume2,162,292
Market Cap77.012M
Beta3.45
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire7 days ago

    Abattis Strengthens Management Team and Provides Company Updates

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide the following corporate updates. The Company is pleased to announce the appointment of Nicole Breitinger as the Company’s corporate secretary. Ms. Breitinger brings considerable experience to her role, having spent more than twenty years providing corporate services to companies across a range of industries.

  • GlobeNewswire21 days ago

    Abattis Prepares to Launch New Products Through Vergence Naturals

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce that it plans to launch a new line of products designed to alleviate pain and inflammation through its wholly owned subsidiary, Vergence Naturals Ltd. (“Vergence”). The launch is anticipated to take place on Cyber Monday and the new product line will be the first of twelve products the Company hopes to launch over a 36-month period. “We are very proud to have developed two products that safely reduce pain and modulate inflammation.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Completes Acquisition of Licensed Dealer Northern Vine Canada

    Northern Vine is a Licensed Dealer (LD) under the provisions of the Canadian Controlled Drugs and Substances Act. The dealer license allows Emerald to participate in the growing market for cannabis analytical testing, which Emerald expects to grow in conjunction with increasing cannabis production volumes in Canada.

  • GlobeNewswirelast month

    Abattis Completes Sale of Northern Vine Interest

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce that it has completed the sale (the “Sale”) of its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) to Emerald Health Therapeutics, Inc. (TSXV:EMH / OTCQX:EMHTF) (“Emerald”) in exchange for $2 million in cash and $4 million in common shares of Emerald, 50% of which are free trading and 50% of which may be sold in 30 days. The share purchase agreement governing the Disposition (the “Agreement”) also provides that, upon Northern Vine and/or Emerald earning gross revenues of $10 million from the sale of products or provision of services to customers introduced by Abattis, Emerald will issue Abattis an additional $4 million in common shares of Emerald.

  • GlobeNewswirelast month

    Abattis Announces Share Buy Back Program

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it intends to proceed with a normal course issuer bid to purchase up to 20,986,909 of its common shares, representing 5% of its current issued and outstanding shares (the “Bid”). The Company is commencing the Bid because it believes that, from time to time, the market price of its common shares may not fully reflect the underlying value of the Company’s business and future prospects. The Company believes that, at such times, the repurchase of its common shares for cancellation would be in the best interests of its shareholders.

  • GlobeNewswire2 months ago

    Abattis Continues to Build on Recent Investments With Plans for Significant Revenue Growth

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update as the Company moves to a phase of building on recent investments and anticipates significant revenue growth in the fourth quarter of 2018. Through its master services agreement with Northern Vine, the Company continues to have preferential access to a licensed lab, which will enable it to progress its research and development partnerships with the University of British Columbia, exploring nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil, and Faculty Brewing Company, developing hemp-infused, cannabinoid-rich, THC-free craft beer. The Company has also recently deployed capital, through its investment in XLABS Therapeutics (ONT) Inc. (“XLABS”), which is developing a 10,000 square foot laboratory in Belleville, Ontario.  Through XLABS, the Company hopes to leverage the experience it obtained through the build out of Northern Vine on a much larger scale.  In accordance with the terms of the investment, Abattis President and CEO, Rob Abenante has joined the board of directors of XLABS.

  • GlobeNewswire2 months ago

    Abattis Completes Investment in XLABS Therapeutics to Launch New Cannabis Lab in Ontario

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that, further to its news release dated June 28, 2018, it has closed its investment in XLABS Therapeutics (ONT) Inc. (“XLABS”). Together, Abattis and XLABS will be launching a new cannabis laboratory in Belleville, Ontario (the “Laboratory”), to service Ontario’s growing cannabis sector. The Laboratory will be housed in a 320,000 square foot building (the “Belleville Facility”), with plans for an initial build-out of 10,000 square feet and future expansion into the remaining 310,000 square feet through organic growth and further joint ventures.

  • GlobeNewswire2 months ago

    Abattis Bioceuticals Expanding Downstream Cannabis Business into Ontario -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Abattis Bioceuticals Corp.'s (ATT.CN) (ATTBF) recent agreement to develop a new laboratory in Ontario, representing a major expansion into Canada’s most populous province. Abattis has been solidifying and growing its vertically integrated cannabis operations in British Columbia for the last few years. With a licensed producer applicant, cannabis-based product development programs, and a mature product distribution network, Abattis is positioned to control and profit from the highest growth sectors of Canada’s cannabis industry.

  • GlobeNewswire2 months ago

    Abattis Enters Into Definitive Agreement to Sell Northern Vine Interest

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) with Emerald Health Therapeutics, Inc. (“Emerald”) to dispose of (the “Disposition”) its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) in exchange for $2 million in cash and $4 million in freely tradeable common shares of Emerald. The Agreement also provides that, upon Northern Vine and/or Emerald earning gross revenues of $10 million from the sale of products or services to customers introduced by Abattis, Emerald will issue Abattis a further $4 million in common shares of Emerald.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Completes Full Acquisition of Licensed Dealer Northern Vine to Advance Product Innovation

    Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) (Emerald) has signed a definitive agreement  (“Agreement”) to acquire the remaining shares of Northern Vine Canada Inc. (Northern Vine), owned by Abattis Bioceuticals Corp. (Abattis) (CSE:ATT) (ATTBF), for $2 million in cash and $4 million in shares of Emerald stock. Northern Vine is a Licensed Dealer (LD) under the provisions of the Canadian Controlled Drugs and Substances Act. “Product innovation is a primary pillar of Emerald’s global business strategy.

  • GlobeNewswire2 months ago

    Abattis Provides Corporate Updates

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to provide the following corporate updates. Abattis has completed a non-brokered private placement for gross proceeds of $2.25 million (the “Proceeds”) through the issuance of 13,235,294 common shares of the Company priced at $0.17 per share. The Company anticipates that the Proceeds will be used to organically grow its existing downstream service division and for general working capital purposes.

  • CNW Group3 months ago

    IIROC Trade Resumption - ATT

    IIROC Trade Resumption - ATT

  • GlobeNewswire3 months ago

    Abattis Enters Into Definitive Agreement to Launch New Cannabis Lab in Ontario

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive investment agreement dated June 27, 2018 (the “Agreement”) with XLABS Therapeutics (ONT) Inc. (“XLABS”) to launch a new Cannabis laboratory in Belleville, Ontario (the “Laboratory”). The Laboratory will be designed to service Ontario’s growing cannabis sector, which currently numbers 59 licensed producers (“LPs”). “This is another very significant milestone for Abattis,” stated Rob Abenante, President and CEO of Abattis.

  • CNW Group3 months ago

    IIROC Trading Halt - ATT

    IIROC Trading Halt - ATT

  • CNW Group3 months ago

    Abattis and BLOCKStrain Execute Letter of Intent for Product Integration and Strategic Partnership

    OTC:ATTBF) ("Abattis") and BLOCKSTRAIN TECHNOLOGY CORP. ("BLOCKStrain") (TSXV: DNAX.V) are pleased to announce that they have signed a letter of intent (the "LOI") to integrate BLOCKStrain's proprietary technology into Abattis's  product and services ecosystem. Through their collaboration, the parties hope to enable Abattis clients to instantly arrange for sales, shipping, testing and analysis of Abattis products and give clients comprehensive visibility over such products over their entire lifecycles. Abattis and BLOCKStrain also intend to explore development and integration opportunities to expand on Abattis's current life sciences and biotechnology services offerings.

  • CNW Group5 months ago

    IIROC Trade Resumption - ATT

    IIROC Trade Resumption - ATT

  • CNW Group5 months ago

    IIROC Trading Halt - ATT

    IIROC Trading Halt - ATT

  • Newsfile5 months ago

    Abattis Completes Acquisition of Remaining Minority Interest in Gabriola Green Farms

    Vancouver, British Columbia--(Newsfile Corp. - April 30, 2018) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce, further to its news release dated April 18, 2018, that it has completed its acquisition of the remaining 10% ownership interest (the "Interest") in its subsidiary, Gabriola Green Farms Inc. ("Gabriola"). Abattis acquired the Interest from CannaNUMUS Blockchain Inc. for $2.5 million. Gabriola is now a wholly-owned subsidiary of the ...

  • Newsfile5 months ago

    Abattis Enters into Agreement to Acquire Remaining Minority Interest in Gabriola Green Farms

    Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce that it has entered into a share purchase agreement to acquire (the "Acquisition") the remaining 10% ownership interest in its subsidiary, Gabriola Green Farms Inc. ("Gabriola")."We are very happy to now own a 100% interest in Gabriola and integrate it as a wholly-owned subsidiary of Abattis. We believe that Gabriola's anticipated LP ...